<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00134901</url>
  </required_header>
  <id_info>
    <org_study_id>#4496-NIDA-12761-2</org_study_id>
    <secondary_id>P50DA012761</secondary_id>
    <nct_id>NCT00134901</nct_id>
  </id_info>
  <brief_title>Effectiveness of Memantine in Treating Cocaine-Dependent Individuals - 2</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Trial of the Effectiveness of Memantine in Treating Cocaine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Research Foundation for Mental Hygiene, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cocaine is one of the most widely abused drugs in the United States. Memantine is a type of
      drug called an NMDA receptor antagonist. It works by decreasing normal excitement in the
      brain. NMDA receptor antagonists have shown to reduce cocaine-induced dopamine release in
      animal models, as well as lessen conditioned cocaine cues. The purpose of this study is to
      determine the effectiveness of memantine in preventing relapse to cocaine use in cocaine
      dependent individuals. In addition, this study will determine whether memantine produces
      better results than a placebo in decreasing cocaine craving, psychological symptoms,
      functional impairment, and discontinuation of treatment in cocaine dependent individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Memantine is a non-competitive NMDA receptor antagonist that works by decreasing normal
      excitement in the brain. Dopamine plays a role in the rewarding and addictive properties of
      cocaine, however, past clinical studies have not been successful in using dopamine agonists
      in treating cocaine dependent individuals. Non-competitive NMDA receptor antagonists have
      shown to reduce cocaine-induced dopamine release in animal models and lessen conditioned
      cocaine cues. This study will evaluate memantine in treating cocaine dependent individuals
      and its ability to prevent relapse to cocaine use. Specifically, the aim of this study is to
      determine if memantine is superior to placebo in decreasing cocaine craving, psychological
      symptoms, functional impairment, and discontinuation of treatment for cocaine abuse.

      Participants will enter a 2-week, single-blind, placebo lead-in phase, during which they will
      visit the clinic three times each week. At each study visit, urine samples and other rating
      assessments will be collected. In addition, participants will attend weekly therapy sessions.
      In order to continue in the trial, participants are required to attend at least four out of
      the first six study visits and both therapy sessions. Eligible participants will then be
      randomly assigned to receive either memantine or placebo for the duration of the 12-week,
      double-blind phase of the trial. Study visits will continue to occur three times each week;
      participants will also receive weekly therapy. Memantine will be taken twice each day.
      Participants who complete the 12-week trial will enter a 2-week lead-out phase, during which
      they will be tapered back to a placebo in a single-blind manner. Weekly psychotherapy
      sessions will continue until the end of Week 14.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weekly Cocaine Use</measure>
    <time_frame>weekly use during length of study participation</time_frame>
    <description>Mean number of cocaine using days per week based on self reported use verified by cocaine toxicology results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cocaine Abstinence Based on Daily Self Reported Cocaine Use</measure>
    <time_frame>reported weekly cocaine use for 12 weeks/ or study participation</time_frame>
    <description>A binary indicator of sustained abstinence, defined as three consecutive weeks of no cocaine use, obtained by self-report and verified using negative urine toxicology results, at any point of the trial;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Cocaine-Related Disorders</condition>
  <arm_group>
    <arm_group_label>Memantine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Memantine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine</intervention_name>
    <description>Memantine</description>
    <arm_group_label>Memantine</arm_group_label>
    <other_name>Memantine 40mg/day</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets DSM-IV criteria for current cocaine dependence

          -  Use of cocaine at least four days in the month prior to enrollment or episodic cocaine
             binges of at least $200 worth at least twice each month (confirmed by urine toxicology
             test)

        Exclusion Criteria:

          -  Meets DSM-IV criteria for major depression, bipolar disorder, schizophrenia, or any
             psychotic disorder other than transient psychosis due to drug abuse

          -  History of seizures in the two years prior to enrollment

          -  History of seizures related to current substance abuse (including cocaine, alcohol, or
             benzodiazepine)

          -  History of an allergic reaction to memantine

          -  Chronic organic mental disorder

          -  Current significant suicidal risk, history of significant suicidal behavior, or any
             suicide attempt within the year prior to enrollment

          -  Pregnant or breastfeeding

          -  Failure to use adequate contraception

          -  Unstable physical disorders that might make participation hazardous, such as
             hypertension, acute hepatitis (individuals with chronic mildly elevated transaminase
             levels at 2 to 3 times the upper normal limit are not excluded if their PT/PTT is
             normal), renal impairment, or diabetes

          -  Current coronary vascular disease, or suspected by an abnormal ECG or history of
             cardiac symptoms

          -  Cardiac conduction system disease, as indicated by QRS duration greater than 0.11

          -  History of failure to respond to a previous trial with memantine

          -  Currently meets DSM-IV criteria for substance dependence or abuse disorder other than
             nicotine or marijuana

          -  Currently taking psychotropic medications, excluding zolpidem or trazodone for
             insomnia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frances R Levin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Foundation for Mental Hygiene, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Foundation for Mental Hygiene, Inc.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stars.columbia.edu</url>
    <description>Substance Treatment and Abuse Research Service (STARS)</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2005</study_first_submitted>
  <study_first_submitted_qc>August 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2005</study_first_posted>
  <results_first_submitted>August 25, 2014</results_first_submitted>
  <results_first_submitted_qc>August 25, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 5, 2014</results_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Frances R Levin</investigator_full_name>
    <investigator_title>Director of Substance Use Disorder</investigator_title>
  </responsible_party>
  <keyword>Cocaine dependence</keyword>
  <keyword>treatment</keyword>
  <keyword>memantine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Individuals who applied for treatment at Columbia University’s Substance Treatment and Research Service (STARS) outpatient clinic in New York City, USA, were recruited for this study. The study recruited from March 2003-February 2007.</recruitment_details>
      <pre_assignment_details>patients entered a 2-week, single-blind placebo lead-in period. To be eligible for randomization, patients were required to attend at least 2 of 4 scheduled therapy sessions and to submit at least 4 of 6 scheduled urine samples during the two weeks of the lead-in period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Memantine</title>
          <description>Memantine 40mg/day</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo daily dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>discontinued intervention</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Memantine</title>
          <description>Memantine 40mg/day</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo daily dose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="81"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" spread="7"/>
                    <measurement group_id="B2" value="40" spread="9"/>
                    <measurement group_id="B3" value="40" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Cocaine Abstinence Based on Daily Self Reported Cocaine Use</title>
        <description>A binary indicator of sustained abstinence, defined as three consecutive weeks of no cocaine use, obtained by self-report and verified using negative urine toxicology results, at any point of the trial;</description>
        <time_frame>reported weekly cocaine use for 12 weeks/ or study participation</time_frame>
        <population>All analyses were performed on an intent-to-treat basis</population>
        <group_list>
          <group group_id="O1">
            <title>Memantine</title>
            <description>Memantine 40mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo daily dose</description>
          </group>
        </group_list>
        <measure>
          <title>Cocaine Abstinence Based on Daily Self Reported Cocaine Use</title>
          <description>A binary indicator of sustained abstinence, defined as three consecutive weeks of no cocaine use, obtained by self-report and verified using negative urine toxicology results, at any point of the trial;</description>
          <population>All analyses were performed on an intent-to-treat basis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Weekly Cocaine Use</title>
        <description>Mean number of cocaine using days per week based on self reported use verified by cocaine toxicology results.</description>
        <time_frame>weekly use during length of study participation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Memantine</title>
            <description>Memantine
Memantine: Memantine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
placebo: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Cocaine Use</title>
          <description>Mean number of cocaine using days per week based on self reported use verified by cocaine toxicology results.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.9"/>
                    <measurement group_id="O2" value="1.3" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Memantine</title>
          <description>Memantine 40mg/day</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo daily dose</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <description>abdominal pain</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>finger fracture</sub_title>
                <description>fingure fracture</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI upset</sub_title>
                <description>GI upset</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <description>nausea</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <description>diarrhea</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <description>insomnia</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>chills</sub_title>
                <description>chills</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <description>fever</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>light headed</sub_title>
                <description>light headed</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>drowsiness</sub_title>
                <description>drowsiness</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle aches</sub_title>
                <description>muscle aches</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>back ache</sub_title>
                <description>back ache</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <description>headache</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <description>anxiety</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <description>rash</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>participants who had achieved abstinence during the lead-in remained abstinent throughout the trial and there was little relapse-like behavior for a medication to address.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Adam Bisaga</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>(646) 774-6155</phone>
      <email>bisagaa@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

